Fierce Pharma December 26, 2024
As the life sciences industry prepares for a new administration, grapples with cutting-edge technology and braces for the potential impact of inflation and supply chain disruptions, there are plenty of challenges in store for 2025—and much to be optimistic about, too.
That’s according to the Deloitte U.S. Center for Health Solutions, which found in a recent survey of 150 C-suite executives across the global life sciences sphere that 75% of respondents are optimistic about the year ahead.
The executives’ hopes for the coming year hinge largely on growth expectations, with 68% of respondents predicting revenue increases at their companies and 57% forecasting margin expansions in 2025, Deloitte said in a press release outlining the results from the poll.
Beyond that...
Today's Sponsors
Today's Sponsor